MMSI

Merit Medical Systems Inc

$86.35

-0.32%
Nov 16, 2026
Bobby Quantitative Model
Merit Medical Systems Inc. designs, develops, manufactures, and markets single-use medical devices used in interventional cardiology, radiology, endoscopy, and related minimally invasive procedures, operating through Cardiovascular and Endoscopy reporting segments with the Cardiovascular franchise generating the majority of revenue. The company occupies a niche but durable position in the medtech supply chain, functioning as a broad-portfolio consolidator of interventional accessories rather than a single-product platform, which gives it sticky hospital relationships and recurring procedural demand. The current investor narrative centers on a sharp margin and earnings inflection: Q3 2026 net income rose to $42.3 million from $27.8 million a year earlier, gross margin improved to 48.2%, and the stock has re-rated dramatically off its spring lows. Debate now hinges on whether this profitability step-change is structural — driven by operating leverage, pricing, and mix — or partly cyclical, and whether the April 2026 View Point Medical acquisition into therapeutic oncology can extend the growth runway despite near-term dilution.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis

BobbyInvestment Opinion: Should I buy MMSI Today?

Rating: Hold with a constructive tilt. The thesis is that Merit's Q3 2026 earnings inflection is real — net income of $42.31M versus $27.76M a year earlier (+52%) on essentially flat gross margin (48.2% vs 48.5%) — but the stock at $86.63 already reflects most of that step-up after a +41.18% six-month run, leaving the risk/reward balanced rather than compelling. The analyst consensus leans constructive (JP Morgan Overweight, Canaccord/BTIG/Needham Buy versus Wells Fargo Equal Weight, B of A Neutral, Freedom Capital Hold), though no explicit price targets were provided, so upside cannot be quantified from the data.

Supporting evidence is genuinely strong on the earnings side: forward PE of 8.41x against consensus EPS of $5.53 (a range of just $5.46-$5.57, under 2% spread) versus a trailing PE of 40.62x implies a massive expected earnings step-up; operating margin expanded to 14.12% from 11.13%; TTM free cash flow is $204.24M with $52.25M generated in Q3 alone; and the balance sheet is flexible with $505.79M cash, a 4.34 current ratio, and 0.57 debt-to-equity. The offsetting data points are that revenue growth is only 8.32% YoY, the PEG of 8.41 flags growth as expensive, ROE is a modest 8.11%, and the stock trades at roughly 92% of its 52-week range after a 7.7% post-earnings gap down on October 30.

The biggest risks that could invalidate the thesis are margin reversion (Q2's 51.4% gross margin already fell to 48.2% in Q3, and a slide back toward the 11% operating-margin historical range would make the trailing 40.6x PE the real valuation), revenue deceleration (sequential revenue flattened from $418.84M in Q2 to $416.24M in Q3), and near-term dilution from the $91.94M View Point Medical oncology acquisition. This Hold would upgrade to Buy if the stock pulls back toward the $80.84-$83.35 support shelf while operating margin holds above 14%, or if forward EPS visibility extends into 2027; it would downgrade to Sell if operating margin falls below 12% or revenue growth decelerates below 5%. Verdict: fairly valued on forward earnings, expensive on trailing earnings — the multiple is the debate, not the numbers.

Sign up to view all

MMSI 12-Month Price Forecast

The forward-looking picture is genuinely two-sided: the earnings inflection is quantified and analyst conviction in near-term numbers is high, but the stock has already re-rated +41.18% in six months and sits near the top of its range, so the easy money has been made. The single variable that resolves the debate is whether the 14%+ operating margin is a structural new baseline or a cyclical peak — if structural, the 8.41x forward PE is deeply undervalued; if it reverts toward 11-12%, the trailing 40.62x becomes the real multiple and the stock is expensive. I would upgrade to bullish on a pullback toward the $80.84-$83.35 support shelf with margins intact, or on a decisive breakout above $94.20; I would downgrade to bearish if operating margin falls below 12% or revenue growth decelerates below 5%. With no explicit analyst price targets in the data, the market rather than the sell side is setting the valuation bar, which argues for patience over chasing.

Historical Price
Current Price $86.35
Average Target $86.35
High Target $99.30
Low Target $73.40

Wall Street consensus

Coverage is moderate, with 5 analysts contributing estimates and a broader institutional rating set of roughly 10 firms. The distribution skews bullish: JP Morgan (Overweight), Canaccord (Buy), BTIG (Buy), and Needham (Buy) are offset by Wells Fargo (Equal Weight), B of A (Neutral), and Freedom Capital (Hold), yielding a consensus leaning constructive but not euphoric. The consensus EPS estimate of $5.53 (range $5.46-$5.57) and revenue estimate of $2.07 billion (range $2.05-$2.08 billion) imply confidence in the earnings inflection; however, specific price targets are not available in the provided data, so implied upside cannot be calculated.

The tight EPS estimate range ($5.46-$5.57, a spread of under 2%) signals strong conviction in near-term numbers, which contrasts with the stock's volatile price action and suggests the debate is about the multiple, not the earnings. Recent rating actions are stable — no upgrades or downgrades in the visible window, with firms reiterating existing stances around the October 30 earnings date. The absence of explicit price targets limits signal strength; investors should treat the consensus Buy/Overweight tilt as directionally positive but recognize that the wide gap between trailing and forward PE means the market, not the analysts, is setting the valuation bar.

Drowning in data?

Find the real signal!

Bulls vs Bears: MMSI Investment Factors

The bull case currently has stronger evidence: the earnings inflection is real and quantified, with net income up 52% YoY on flat gross margins, and the forward PE of 8.41x versus trailing 40.62x means the market is pricing in a massive earnings step-up that analysts strongly expect (EPS range under 2% spread). The balance sheet (current ratio 4.34, D/E 0.57, $505.79M cash) and $204.24M TTM free cash flow provide a cushion. However, the bear case is not trivial: 8.32% revenue growth is only mid-single-digit, the PEG of 8.41 is expensive, and the 7.7% post-earnings gap shows how fragile sentiment is at 92% of the 52-week range. The single most important tension is whether the 14%+ operating margin is a structural new baseline or a cyclical peak — if it holds, the forward multiple is cheap; if it reverts toward the 11-12% historical range, the trailing 40.6x PE becomes the real valuation and the stock is expensive.

Bullish

  • Operating leverage drives earnings inflection: Q3 2026 net income jumped to $42.31M (10.16% net margin) from $27.76M (7.22%) a year earlier, a 52% increase, while gross margin was essentially flat at 48.2% vs 48.5%. This means the earnings gain came from operating leverage rather than gross-margin expansion, a more durable driver. Operating income rose to $58.76M (14.12% margin) from $42.75M (11.13%), and EBITDA reached $94.96M (22.81% margin) from $79.54M (20.70%).
  • Forward PE of 8.4x implies deep value: The trailing PE of 40.62x collapses to a forward PE of 8.41x against the consensus EPS estimate of $5.53, an extraordinarily wide gap. If forward earnings materialize, the stock trades at a fraction of the medical instruments sector's high-teens to low-20s EV/EBITDA multiple. The tight EPS estimate range of $5.46-$5.57 (under 2% spread) signals strong analyst conviction in the near-term numbers.
  • Solid balance sheet and cash generation: The current ratio of 4.34 and debt-to-equity of 0.57 provide substantial financial flexibility, with $505.79M in cash at Q3 2026. Free cash flow TTM is $204.24M, with quarterly FCF of $52.25M in Q3 and $51.09M in Q2. The company funded a $91.94M acquisition in Q2 2026 without stressing leverage.
  • Steady revenue growth with oncology optionality: Q3 2026 revenue of $416.24M grew 8.32% YoY versus $384.26M, and the trailing four-quarter sequence shows a clear step-up in H1 2026. The April 2026 View Point Medical acquisition into therapeutic oncology extends the growth runway beyond the core interventional accessories franchise. The therapeutic segment at $140.51M is the larger disclosed line, giving the oncology push a meaningful base.

Bearish

  • Trailing valuation is rich at 40.6x PE: The trailing PE of 40.62x is a clear premium to the medical instruments sector, and the PEG of 8.41 flags growth as expensive relative to the multiple. The 48.65% gross margin and 12.17% operating margin are respectable but not best-in-class, so the premium rests entirely on the earnings trajectory rather than current profitability. Any execution stumble would leave the trailing multiple looking stretched.
  • Post-earnings gap signals fragility: The stock gapped roughly 7.7% from $93.39 to $86.24 on October 30, then retested $84.16 on November 3 before rebounding to $90.63 on November 4. This volatile shakeout pattern is consistent with post-earnings repositioning and shows how quickly sentiment can reverse. The -35.28% max drawdown confirms meaningful prior volatility and above-market risk.
  • Revenue growth is only mid-single-digit: Q3 2026 revenue grew 8.32% YoY, and the sequential trend flattened from $418.84M in Q2 to $416.24M in Q3. The 1-year change of -0.88% versus SPY's +12.27% (relative strength -13.15) reveals the rally is a recovery from a prior collapse rather than a clean multi-year advance. A PEG of 8.41 on 8% revenue growth is hard to justify without sustained margin expansion.
  • Margin reversion risk from Q2 peak: Q2 2026 gross margin of 51.4% was an outlier high, and the reversion to 48.2% in Q3 suggests mix normalization. The key question is whether the 14%+ operating margin is the new baseline or a peak. If gross margin continues to normalize toward the 48.5% historical level, the operating leverage story weakens materially.

MMSI Technical Analysis

Merit Medical is in a powerful, sustained uptrend that has recovered from a deep drawdown. The stock trades at $86.63, which is approximately 92% of its 52-week range (low near $60.65 in early June, high of $94.20 on October 26), placing it firmly in the upper quartile of its range and signaling momentum leadership rather than a value setup. The 6-month change of +41.18% versus a 2.13% gain for SPY underscores how violent the re-rating has been, with relative strength over six months at +39.05. Notably, the 1-year change of -0.88% versus SPY's +12.27% (relative strength -13.15) reveals that the rally is a recovery from a prior collapse rather than a clean multi-year advance, and the -35.28% max drawdown confirms meaningful prior volatility.

Short-term momentum has cooled and is diverging from the medium-term trend. The 1-month change is -0.61% and the 3-month change is -4.55%, both a sharp deceleration from the +41.18% six-month surge, indicating the stock is consolidating after its August-October run. This divergence is not necessarily bearish: the 1-month relative strength versus SPY is +1.65, meaning MMSI is modestly outperforming a soft tape (SPY -2.26% over one month), which suggests the pullback is orderly rather than distribution-driven. The most telling data point is the October 30 gap from $93.39 to $86.24 — a roughly 7.7% single-session drop — followed by a retest of $84.16 on November 3 and a rebound to $90.63 on November 4, a volatile shakeout pattern consistent with post-earnings repositioning rather than trend failure.

Key technical levels are well defined. Resistance sits at the $93.94-$94.20 double-top zone from late October; a decisive breakout above $94 would confirm resumption of the primary uptrend and likely target new highs. Support is layered at $84.16 (the November 3 low) and, more importantly, the $80.84-$83.35 shelf from late July, with the 52-week low near $60.65 as the ultimate floor. Beta is not available in the provided data, but the -35.28% max drawdown and the 7.7% single-day gap imply above-market volatility, warranting smaller position sizing and wider stops than a typical large-cap medtech name.

Beta

—

—

Max Drawdown

-35.3%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+1.5%

Cumulative gain past year

PeriodMMSI ReturnS&P 500
1m-3.2%-3.0%
3m-3.3%-3.6%
6m+33.9%-0.2%
1y+1.5%+10.1%
ytd-0.1%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

MMSI Fundamental Analysis

Revenue is growing at a steady, mid-single-digit pace with recent acceleration. Q3 2026 revenue of $416.24 million grew 8.32% year over year versus $384.26 million in Q3 2025, and the trailing four-quarter sequence — $394.18 million (Q4 2025), $381.88 million (Q1 2026), $418.84 million (Q2 2026), $416.24 million (Q3 2026) — shows a clear step-up in the first half of 2026 followed by a plateau. The therapeutic segment at $140.51 million is the larger disclosed line versus $2.01 million in other product/service revenue, and the View Point Medical acquisition is intended to deepen the oncology franchise. The growth trend supports a durable, procedure-driven compounding story, though the sequential flattening from Q2 to Q3 bears watching for signs of deceleration.

Profitability has inflected sharply and is the core of the bull case. Q3 2026 net income of $42.31 million (10.16% net margin) rose from $27.76 million (7.22% margin) a year earlier, while gross margin held at 48.2% versus 48.5% — essentially stable, meaning the earnings gain came from operating leverage, not gross-margin expansion. Operating income jumped to $58.76 million (14.12% operating margin) from $42.75 million (11.13%), and EBITDA rose to $94.96 million (22.81% EBITDA margin) from $79.54 million (20.70%). The Q2 2026 gross margin of 51.4% was an outlier high, and the reversion to 48.2% in Q3 suggests mix normalization; the key question is whether the 14%+ operating margin is the new baseline or a peak.

Balance sheet and cash generation are solid but not fortress-like. Debt-to-equity is 0.57, the current ratio is a very strong 4.34, and cash stood at $505.79 million at Q3 2026, giving ample liquidity. Free cash flow TTM is $204.24 million, with quarterly FCF of $52.25 million in Q3 2026 and $51.09 million in Q2, though Q1 2026 FCF was only $23.92 million due to a $32.07 million working-capital drag. ROE of 8.11% is modest for a medtech compounder, reflecting a low-margin historical base now improving; the company funds growth internally and made a $91.94 million acquisition in Q2 2026 without stressing leverage, a sign of financial flexibility.

Quarterly Revenue

$416244000.0B

2026-09

Revenue YoY Growth

+8.3%

YoY Comparison

Gross Margin

48.2%

Latest Quarter

Free Cash Flow

$204243000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Product and Service, Other
Therapeutic

Open an Account, get $2 TSLA now!

Valuation Analysis: Is MMSI Overvalued?

Because net income is positive ($42.31 million in Q3 2026), the PE ratio is the primary metric. The trailing PE is 40.62x versus a forward PE of 8.41x — an extraordinarily wide gap that implies the market expects a massive earnings step-up, consistent with the analyst consensus EPS estimate of $5.53 versus the trailing EPS of roughly $2.13. This gap is the single most important valuation signal: if forward earnings materialize, the stock is cheap; if they disappoint, the trailing multiple looks rich.

On a peer basis, the stock carries a premium across most multiples. PS is 3.44x, PB is 3.29x, EV/EBITDA is 17.06x, and PCF is 17.53x, with a PEG of 8.41 that flags growth as expensive relative to the multiple. Against a medical instruments sector that typically trades in the high-teens to low-20s EV/EBITDA, the 17.06x is roughly in line to modestly above, while the 40.6x trailing PE is a clear premium that must be justified by the margin inflection and the oncology expansion. The 48.65% gross margin and 12.17% operating margin are respectable but not best-in-class, suggesting the premium rests on the earnings trajectory rather than current profitability.

Historically, the stock's PE has ranged from roughly 25x (Q1 2026) to over 50x (Q1 2025), and the current 40.6x sits in the upper-middle of that band. The PS ratio of 3.44x, however, is near the low end of its multi-year range (which peaked above 17x in Q1 2025), reflecting the sharp revenue base expansion and the stock's prior de-rating. This mixed picture — elevated PE but compressed PS — suggests the market is pricing in margin-driven earnings growth rather than multiple expansion, leaving less room for error on execution.

PE

40.6x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 25x~60x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

17.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the durability of the margin inflection and the modest return profile. The 14.12% Q3 2026 operating margin compares to 11.13% a year earlier and 11.52% in Q1 2026, so the improvement is recent and not yet proven across a full cycle; Q2 2026's 51.4% gross margin already reverted to 48.2% in Q3, showing mix sensitivity. ROE of 8.11% is low for a medtech compounder, and the $91.94M View Point Medical acquisition is expected to dilute earnings near term while adding integration and amortization risk. Interest expense of $7.33M in Q3 2026 on debt-to-equity of 0.57 is manageable given $505.79M in cash, but the company depends on continued earnings growth to justify its trailing 40.6x PE.

Market and competitive risks stem from valuation compression and the stock's demonstrated volatility. The trailing PE of 40.62x sits in the upper-middle of its historical 25x-50x band, while the PEG of 8.41 flags growth as expensive; if the forward EPS of $5.53 disappoints, the multiple has substantial room to compress toward the 25x low. The stock trades at roughly 92% of its 52-week range after a +41.18% six-month run versus SPY's +2.13%, meaning much of the good news is priced in. Beta is not available, but the -35.28% max drawdown and the 7.7% single-session gap on October 30 imply above-market volatility and sector-rotation sensitivity. Competition in interventional accessories is fragmented, and the oncology expansion pits Merit against larger, better-capitalized therapeutic players.

The worst-case scenario is a margin reversion combined with an earnings miss: if operating margin falls back toward the 11% historical range and forward EPS guidance is cut, the market would re-rate the stock on trailing earnings, compressing the multiple toward 25x. From the current $86.63, a decline to the 52-week low of $60.65 would represent roughly -30%, and the stock has already demonstrated a -35.28% max drawdown. A more moderate adverse case would retest the $80.84-$83.35 late-July shelf, about -4% to -7%, while a full sentiment reversal toward the June low implies a loss of roughly -30% from current levels. Investors should size positions for this volatility and watch the $84.16 November 3 low as the first warning level.

FAQ

The most severe risk is margin reversion: the 14.12% Q3 2026 operating margin compares to 11.13% a year earlier and 11.52% in Q1 2026, and Q2's 51.4% gross margin already fell to 48.2% in Q3 — if the improvement proves cyclical, the trailing 40.6x PE becomes the real valuation and the stock is expensive. Second is revenue deceleration: growth is only 8.32% YoY and sequential revenue flattened from $418.84M in Q2 to $416.24M in Q3, which against a PEG of 8.41 leaves little cushion. Third is company-specific dilution and integration risk from the $91.94M View Point Medical oncology acquisition, which is expected to dilute near-term earnings and adds amortization to an already modest 8.11% ROE. Fourth is market and volatility risk: the stock has a -35.28% max drawdown, gapped 7.7% in a single session on October 30, and trades at roughly 92% of its 52-week range after a +41.18% six-month run, making it vulnerable to sentiment reversal and sector rotation.

The 12-month forecast splits into three scenarios. The base case (50% probability, $85-$95) assumes operating margin holds in the 13-14% band, revenue grows 7-9%, gross margin stabilizes near 48-49%, and consensus EPS of $5.53 materializes, letting the 8.41x forward PE gain credibility without a full re-rating. The bull case (25%, $100-$110) requires the margin inflection to prove structural with operating margin above 14%, a decisive breakout above the $93.94-$94.20 double-top, and early oncology contribution, driving a re-rating toward the sector's high-teens EV/EBITDA benchmark. The bear case (25%, $60-$75) assumes margin reverts toward 11-12%, forward EPS is cut, and the stock retests the $80.84-$83.35 shelf before approaching the $60.65 52-week low, a roughly 30% decline. The base case is most likely, and its key assumption is that the 14% operating margin is a durable new baseline rather than a cyclical peak.

The answer depends entirely on which earnings base you trust. On trailing numbers the stock is expensive: a 40.62x PE, 3.44x PS, 3.29x PB, 17.06x EV/EBITDA, and a PEG of 8.41 all sit at a premium to a medical instruments sector that typically trades in the high-teens to low-20s EV/EBITDA. On forward numbers it looks deeply undervalued, with an 8.41x forward PE against consensus EPS of $5.53 — a gap so wide it implies the market expects a transformative earnings step-up. The mixed signal of an elevated PE but a compressed PS (3.44x versus a multi-year peak above 17x) suggests the market is pricing margin-driven earnings growth rather than multiple expansion. Net, the stock is fairly valued on forward earnings and expensive on trailing earnings; the multiple, not the earnings, is the debate, and the market is paying for execution that has not yet been proven across a full cycle.

From a risk/reward standpoint, MMSI is a reasonable but not compelling buy at $86.63. The bull case rests on a forward PE of 8.41x against consensus EPS of $5.53 (a tight $5.46-$5.57 range, under 2% spread) versus a trailing PE of 40.62x, implying a massive expected earnings step-up that would make the stock cheap if delivered. Supporting that, Q3 2026 net income rose 52% to $42.31M on flat gross margin, TTM free cash flow is $204.24M, and the balance sheet is flexible with $505.79M cash and a 4.34 current ratio. The downside is that the stock has already re-rated +41.18% in six months and sits at roughly 92% of its 52-week range, with a 7.7% post-earnings gap on October 30 showing how fragile sentiment is. It is a good buy for investors who can tolerate a pullback toward the $80.84-$83.35 support shelf and who believe the 14%+ operating margin is structural; it is a poor entry for anyone chasing the recent momentum without that conviction.

MMSI is better suited to a medium-to-long-term holding than to short-term trading. The fundamental case — a procedure-driven interventional device franchise with $204.24M TTM free cash flow, a 4.34 current ratio, and 0.57 debt-to-equity — rewards patience as the margin story is validated across quarters, but the stock's demonstrated volatility (a -35.28% max drawdown and a 7.7% single-session gap on October 30) makes it a poor vehicle for tight-stop traders. There is no dividend (0% yield, 0% payout), so total return depends entirely on earnings delivery and multiple re-rating, which argues for a horizon long enough to let the forward EPS of $5.53 prove out. A concrete suggested minimum holding period is 12-18 months, spanning at least four quarterly reports, so the investor can observe whether operating margin holds above 13% and whether the View Point Medical oncology acquisition begins contributing revenue. Position sizing should be modest given the above-market volatility implied by the drawdown profile.